The size of the Safety Syringes Market in the Asia Pacific was calculated at USD 976.10 million in 2021. It is further predicted to grow and worth USD 1638.86 million by 2026, growing at a CAGR of 10.92% between 2021 to 2026.
There has been a constant demand to safeguard health care workers from accidental needle-stick injuries and healthcare-acquired infections. Safety syringes are specifically designed to meet this need.
With the rise in the incidence of needlestick injuries, new initiatives and legislation by governments to incorporate the practice of safety syringes, favorable reimbursement policies, and upgraded safety mechanisms for syringes boost the growth of the Asia-Pacific safety syringes market. At present, quite a few countries have enforced regulations to ensure the compulsory use of safety syringes to prevent needlestick injuries and confine needle re-use. These regulations are expected to increase the common usage of safety syringes as compared to conventional syringes.
However, the availability of alternative drug delivery methods, the high price of safety syringes, and their ignorance in developing countries due to lack of proper awareness about healthcare and safety issues are few factors off-putting the growth of the Asia-Pacific safety syringes market.
This research report on the APAC Safety Syringes Market has been segmented and sub-segmented into the following categories:
By Technology:
By Therapy:
By End Users:
By Country:
Regionally, the Asia-Pacific region is expected to register the highest growth rate within the forecast period. The market in this region is currently experiencing a paradigm shift in using safety syringes over conventional ones.
Promising companies in the APAC Safety Syringes Market profiled in this report are Covidien plc, Retractable Technologies Inc., Becton, Dickinson & Company, Terumo Corporation, Unilife Corporation, Revolutions Medical Corporation, Smiths Medical, Sol-Millennium, Ultimed Inc., and Axel Bio Corporation.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Technology
5.1.1 Retractable safety syringes
5.1.1.1 Automatic retractable safety syringes
5.1.1.2 Manual retractable safety syringes
5.1.2 Non-Retractable safety syringes
5.1.2.1 Sheathing tube syringes
5.1.2.2 Sliding needle cover syringes
5.1.2.3 Hinged needle cover syringes
5.2 By Therapy
5.2.1 Insulin
5.2.2 Glucagon-like peptide-1 (glp-1)
5.2.3 Tuberculosis
5.2.4 Growth hormones
5.3 By End User
5.3.1 Hospitals
5.3.2 Home Care
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Becton, Dickinson & Company
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Covidien plc
8.3 Revolutions Medical Corporation
8.4 Retractable Technologies, Inc.
8.5 Smiths Medical
8.6 Unilife Corporation
8.7 Terumo Corporation
8.8 Sol-Millennum
8.9 Ultimed, Inc.
8.10 Axel Bio Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
